Edison Talks- Interview with CEO of InMed Pharmaceuticals

Published on 21-01-2020 08:20:19
Edison Talks- Interview with CEO of InMed Pharmaceuticals

00:00
00:00

In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO of InMed Pharmaceuticals, the Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Max and Eric discuss Cannabinol (CBN), the minor cannabinoid at the heart of InMed’s programs, why the company chose it and the advantages it may have over cannabiodiol (CBD) and tetrahydrocannabinol (THC).

01:32 Overview of InMed Pharmaceuticals
02:21 Introduction to Cannabinol (CBN), the cannabinoid at the heart of InMed’s epidermolysis bullosa (EB) and glaucoma programs
05:55 Is CBN psychoactive?
08:37 Why did InMed choose CBN for EB?
13:11 Can CBN be used for the treatment of glaucoma?
16:27 How does InMed source CBN?
19:13 Please describe the program in EB
26:31 What are the key upcoming milestones for InMed?